These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32559572)

  • 1. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Shimaoka M
    Thromb Res; 2020 Sep; 193():146-153. PubMed ID: 32559572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.
    Wada H; Ichikawa Y; Ezaki M; Shiraki K; Moritani I; Yamashita Y; Matsumoto T; Masuya M; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients.
    Hasegawa M; Tone S; Wada H; Naito Y; Matsumoto T; Yamashita Y; Shimaoka M; Sudo A
    Clin Appl Thromb Hemost; 2021; 27():10760296211012094. PubMed ID: 34027710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Sakano Y; Nishii H; Tamaki S; Suzuki K; Tawara I; Yamashita Y; Shimaoka M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999423
    [No Abstract]   [Full Text] [Related]  

  • 5. The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Sakano Y; Nishii H; Shimaoka M
    Clin Appl Thromb Hemost; 2021; 27():1076029620976913. PubMed ID: 33606948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis.
    Fukui S; Wada H; Ikeda K; Kobayashi M; Shimada Y; Nakazawa Y; Mizutani H; Ichikawa Y; Nishiura Y; Moritani I; Yamanaka Y; Inoue H; Shimaoka M; Shimpo H; Shiraki K
    Clin Appl Thromb Hemost; 2024; 30():10760296241246002. PubMed ID: 38591954
    [No Abstract]   [Full Text] [Related]  

  • 7. Clot Waveform Analysis for Hemostatic Abnormalities.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
    Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms.
    Kobayashi M; Wada H; Fukui S; Mizutani H; Ichikawa Y; Shiraki K; Moritani I; Inoue H; Shimaoka M; Shimpo H
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Reevaluation of Thrombin Time Using a Clot Waveform Analysis.
    Wada H; Ichikawa Y; Ezaki M; Matsumoto T; Yamashita Y; Shiraki K; Shimaoka M; Shimpo H
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis.
    Kamon T; Horie S; Inaba T; Ito N; Shiraki K; Ichikawa Y; Ezaki M; Shimpo H; Shimaoka M; Nishigaki A; Shindo A; Wada H
    Clin Appl Thromb Hemost; 2023; 29():10760296231161591. PubMed ID: 36872898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of platelets and platelet-derived material on the activated partial thromboplastin time (Cephotest) coagulation test.
    Mendelsohn EE; Solum NO; Brosstad F
    Scand J Clin Lab Invest; 2005; 65(4):321-32. PubMed ID: 16076687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
    Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.
    Iberahim S; Muhamat Yusoff R; Mohd Noor NH; Hassan R; Ramli NN; Bahar R; Zulkafli Z; Wan Ab Rahman WS; Ab Ghani AS
    Cureus; 2024 Jan; 16(1):e51483. PubMed ID: 38304638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis.
    Haku J; Nogami K; Matsumoto T; Ogiwara K; Shima M
    J Thromb Haemost; 2014; 12(3):355-62. PubMed ID: 24354697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the Clot Waveform Analysis.
    Wada H; Matsumoto T; Ohishi K; Shiraki K; Shimaoka M
    Clin Appl Thromb Hemost; 2020; 26():1076029620912027. PubMed ID: 32862666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activated partial thromboplastin time-clot waveform analysis in hemophilia: Does it help in differentiation?
    Mannan KA; Kumar N; Ahluwalia J; Hans C; Kler A; Prakash G; Jain R
    Int J Lab Hematol; 2023 Apr; 45(2):241-249. PubMed ID: 36495061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
    Prasad R; Sen P
    Phys Chem Chem Phys; 2017 Aug; 19(33):22230-22242. PubMed ID: 28799584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.